View in EDS

An Exosome‐Based Vaccine Platform Imparts Cytotoxic T Lymphocyte Immunity Against Viral Antigens

Saved in:
Bibliographic Details
Title: An Exosome‐Based Vaccine Platform Imparts Cytotoxic T Lymphocyte Immunity Against Viral Antigens
Authors: Anticoli S., Manfredi F., Chiozzini C., Arenaccio C., Olivetta E., Ferrantelli F., Capocefalo A., Falcone E., Ruggieri A., Federico M.
Source: Biotechnology Journal. 13
Publisher Information: Wiley, 2018.
Publication Year: 2018
Subject Terms: 0301 basic medicine, Genetic Vectors, Viral Vaccines, Exosomes, Cell Line, Genes, nef, 3. Good health, Mice, 03 medical and health sciences, CTL immunity, DNA immunization, Ebola virus, exosomes, HIV-1 Nef, Animals, Antigens, Viral, HEK293 Cells, Humans, Particle Size, T-Lymphocytes, Cytotoxic
Description: Exosomes are 50–150 nm sized nanovesicles released by all eukaryotic cells. The authors very recently described a method to engineer exosomes in vivo with the E7 protein of Human Papilloma Virus (HPV). This technique consists in the intramuscular injection of a DNA vector expressing HPV‐E7 fused at the C‐terminus of an exosome‐anchoring protein, that is, Nefmut, the authors previously characterized for its high levels of incorporation in exosomes. In this configuration, the ≈11 kDa E7 protein elicited a both strong and effective antigen‐specific cytotoxic T lymphocyte (CTL) immunity. Attempting to establish whether this method could have general applicability, the authors expanded the immunogenicity studies toward an array of viral products of various origin and size including Ebola Virus VP24, VP40 and NP, Influenza Virus NP, Crimean–Congo Hemorrhagic Fever NP, West Nile Virus NS3, and Hepatitis C Virus NS3. All antigens appeared stable upon fusion with Nefmut, and are uploaded in exosomes at levels comparable to Nefmut. When injected in mice, DNA vectors expressing the diverse fusion products elicited a well detectable antigen‐specific CD8+ T cell response associating with a cytotoxic activity potent enough to kill peptide‐loaded and/or antigen‐expressing syngeneic cells. These data definitely proven both effectiveness and flexibility of this innovative CTL vaccine platform.
Document Type: Article
Language: English
ISSN: 1860-7314
1860-6768
DOI: 10.1002/biot.201700443
Access URL: https://pubmed.ncbi.nlm.nih.gov/29274250
https://moh-it.pure.elsevier.com/en/publications/an-exosome-based-vaccine-platform-imparts-cytotoxic-t-lymphocyte-
https://onlinelibrary.wiley.com/doi/10.1002/biot.201700443
https://iris.uniroma3.it/handle/11590/374107
https://www.ncbi.nlm.nih.gov/pubmed/29274250
https://pubmed.ncbi.nlm.nih.gov/29274250/
https://hdl.handle.net/11590/374107
https://doi.org/10.1002/biot.201700443
Rights: Wiley Online Library User Agreement
Accession Number: edsair.doi.dedup.....3f573137fdbc52cccaeb76d71df340ff
Database: OpenAIRE
Description
Abstract:Exosomes are 50–150 nm sized nanovesicles released by all eukaryotic cells. The authors very recently described a method to engineer exosomes in vivo with the E7 protein of Human Papilloma Virus (HPV). This technique consists in the intramuscular injection of a DNA vector expressing HPV‐E7 fused at the C‐terminus of an exosome‐anchoring protein, that is, Nefmut, the authors previously characterized for its high levels of incorporation in exosomes. In this configuration, the ≈11 kDa E7 protein elicited a both strong and effective antigen‐specific cytotoxic T lymphocyte (CTL) immunity. Attempting to establish whether this method could have general applicability, the authors expanded the immunogenicity studies toward an array of viral products of various origin and size including Ebola Virus VP24, VP40 and NP, Influenza Virus NP, Crimean–Congo Hemorrhagic Fever NP, West Nile Virus NS3, and Hepatitis C Virus NS3. All antigens appeared stable upon fusion with Nefmut, and are uploaded in exosomes at levels comparable to Nefmut. When injected in mice, DNA vectors expressing the diverse fusion products elicited a well detectable antigen‐specific CD8+ T cell response associating with a cytotoxic activity potent enough to kill peptide‐loaded and/or antigen‐expressing syngeneic cells. These data definitely proven both effectiveness and flexibility of this innovative CTL vaccine platform.
ISSN:18607314
18606768
DOI:10.1002/biot.201700443